Albiogen

History

2023: P-Pharm's exit from company capital

At the end of June 2023, it became known that the manufacturer of drugs "R-Farm," founded by businessman Alexei Repik, left the capital of the distributor of foreign equipment for genetic research "Albiogen."

According to the Vedomosti newspaper, the R-Pharm group of companies transferred 99% of its shares in Albiogen to A-Gen. The latter in equal proportions belongs to the general director of Albiogen Andrei Frolov and the minority shareholder of the distributor Alexander Yakovlevsky. He is the owner of the remaining 1% in Albiogen. The terms of the deal were not disclosed, but it is noted that information about it is reflected in SPARK-Interfax on June 23, 2023.

R-Pharm withdrew from Albiogen's capital

According to Frolov, the company's withdrawal from the R-Farm group is associated with the reorganization of the business model. At the same time, the goals and objectives of the supplier will remain the same - the promotion of technologies for genetic research of a new generation. At the same time, the deal will allow the pharmaceutical company to protect the asset from sanctions restrictions. Albiogen specializes in supplying Illumina equipment to Russia for sequencing, genotyping and studying gene expression. However, in the current geopolitical situation, difficulties arose with the shipment of equipment.

The financial report of the American biotech company Illumina for the quarter ended April 2, 2023, states that sanctions and export restrictions, along with additional economic and political factors, have affected the ability to supply equipment to the Russian market. And in February 2023, the founder of the R-Farm group of companies, Alexei Repik, was included in the sanctions list. In Britain 2022, Repik ceased to be the owner of R-Farm Holding, the head structure of R-Farm. The company is owned by management; in addition, 1% is owned by Cypriot RJ Pharma Holdings Limited, and 10% is owned. the JapaneseMitsui^[1]

Notes